GRI

NASDAQ 已收盘

GRI Bio

1.12 USD
0.000.00%
盘后 1.12 0.00%
2026-11-20
市值
$2.45M
市盈率
—
EPS
-5.74
股息率
—
52 周区间
1.09 – 64.12
成交量
25.07K
Beta
-0.59
目标价
18.50
52W 低 1.0952W 高 64.12
价格走势

公司简介

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells ...